Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 267-012-8 | CAS number: 67762-34-9 This substance is identified by SDA Substance Name: C8-C18 and C18 unsaturated alkyl carboxylic acid zinc salt and SDA Reporting Number: 01-006-09.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 022
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosomal Aberration Test)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- Zinc dioctanoate
- EC Number:
- 209-156-6
- EC Name:
- Zinc dioctanoate
- Cas Number:
- 557-09-5
- Molecular formula:
- C16H30O4Zn
- IUPAC Name:
- zinc(II) octanoate
- Reference substance name:
- Zinc decanoate
- EC Number:
- 235-909-3
- EC Name:
- Zinc decanoate
- Molecular formula:
- C10H20O2.1/2Zn
- IUPAC Name:
- zinc(II) decanoate
- Reference substance name:
- Zinc dilaurate
- EC Number:
- 219-518-5
- EC Name:
- Zinc dilaurate
- Cas Number:
- 2452-01-9
- Molecular formula:
- C12H24O2.1/2Zn
- IUPAC Name:
- zinc(II) dodecanoate
- Reference substance name:
- Zinc dimyristate
- EC Number:
- 240-369-7
- EC Name:
- Zinc dimyristate
- Cas Number:
- 16260-27-8
- Molecular formula:
- C28H54O4Zn
- IUPAC Name:
- zinc(II) tetradecanoate
- Reference substance name:
- Zinc dipalmitate
- EC Number:
- 225-652-5
- EC Name:
- Zinc dipalmitate
- Cas Number:
- 4991-47-3
- Molecular formula:
- C16H32O2.1/2Zn
- IUPAC Name:
- zinc(II) hexadecanoate
- Reference substance name:
- Zinc distearate
- EC Number:
- 209-151-9
- EC Name:
- Zinc distearate
- Cas Number:
- 557-05-1
- Molecular formula:
- C18H36O2.1/2Zn
- IUPAC Name:
- zinc(II) octadecanoate
- Reference substance name:
- Zinc dioleate
- EC Number:
- 209-154-5
- EC Name:
- Zinc dioleate
- Cas Number:
- 557-07-3
- Molecular formula:
- C18H34O2.1/2Zn
- IUPAC Name:
- zinc(II) 9-octadecenoate
- Reference substance name:
- Zinc dilinoleate
- EC Number:
- 235-870-2
- EC Name:
- Zinc dilinoleate
- Cas Number:
- 13014-44-3
- Molecular formula:
- C36H62O4Zn
- IUPAC Name:
- zinc(II) 9,12-octadecdienoate
- Test material form:
- solid: bulk
Constituent 1
Constituent 2
Constituent 3
Constituent 4
Constituent 5
Constituent 6
Constituent 7
Constituent 8
Method
Species / strain
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Details on mammalian cell type (if applicable):
- The Chinese Hamster Lung(CHL/IU) cell line was used. Modal chromosome number of CHL/IU cell
line is 25 and doubling time is about 15 hours. The CHL/IU cell line has a high detection sensitivity,
is commonly used in in vitro chromosomal aberration test and recommended in the regulatory
guidelines. - Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- 2.6.1. S9 fraction
Species : Rat
Sex : Male
Strain : Sprague-Dawley
Supplier : Molecular Toxicology, Inc.
Storage condition : Frozen(-20 °C below)
Product No. : 11-01L
Lot No. : 4504
Inductive material : Aroclor 1254-induced rat liver S-9
2.6.2. S9 cofactor
Name : Cofactor Ⅰ
Manufacturer : Genogen Co., Ltd.
Lot No. : 220330-I
Storage condition : Frozen(-70±20 °C)
2.6.3. Concentration of S9 Mix
Composition of S9 Mix mL (Final concentration)
S9 fraction 1 (10 % v/v S9)
Cofactor I
0.4 mol/L MgCl2 0.2 (8 μmol/mL)
1.65 mol/L KCl 0.2 (33 μmol/mL)
1.0 mol/L glucose-6-phosphate 0.05 (5 μmol/mL)
0.1 mol/L NADPH 0.4 (4 μmol/mL)
0.1 mol/L NADH 0.4 (4 μmol/mL)
0.2 mol/L sodium phosphate buffer(0.2 M SPB, pH7.4) 5.0 (100 μmol/mL)
Purified water 2.75 -
Total volume 10
S9 Mix was prepared by mixing the S9 fraction and cofactor, but mixing so that the concentration of S9 fraction is 10 %, and then was used while maintaining the refrigerated state(-1~10 °C). S9 Mix
was treated with 0.5 mL/5 mL total volume/T-25 flask and used at a concentration of 1%(v/v) in the final medium. Enzyme activity was confirmed by chromosomal aberration of B[a]P. - Test concentrations with justification for top dose:
- Based on results in the concentration range finding study, the lowest concentration at which precipitation of the test substance was observed until the end of treatment in 6-hour treatment series in the presence of metabolic activation system was set as the highest concentration. In case of 6-hour treatment series and 24-hour treatment series in the absence of metabolic activation system, highest concentration indicating 45±5 % RICC was selected. It was serially diluted to consist of three concentration levels by the common ratio of 2. The prepared test substance was dissolved in the vehicle. The negative and positive control group were added. The positive control was treated at 5 μg/mL of B[a]P in the 6-hour treatment series in presence of metabolic activation system. And, the positive control was treated at 0.2 μg/mL of 4NQO in the 6-hour treatment series and 24-hour treatment series in absence of metabolic activation system. After preparing specimen from all treatment series, metaphase cells were checked to determine whether test substance induce genotoxicity. Concentrations in the main study are presented in the table below.
- Vehicle / solvent:
- Tetrahydrofuran (THF)
Controls
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- yes
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- benzo(a)pyrene
- Evaluation criteria:
- If the test substance meets all the following criteria, it was judged as positive, and if it does not meet all criteria, it was judged as negative.
- When at least one treatment group of test substance shows a statistically significant increase in the frequency of the metaphase cells with structural or numerical chromosomal aberration compared to the negative control group.
- When increases of frequency of metaphase cells with structural or numerical chromosomal aberration in the treatment group of test substance is concentration-related
- When at least one treatment group of test substance is outside the 95 % confidence range of the historical control data of the negative control group. - Statistics:
- Statistical analysis was performed by a chi-squared test using the SPSS program for the frequency of the metaphase cells (excluding gaps) with structural and numerical chromosomal aberration in the negative control group, treatment group of test substance and positive control group.
The result was judged to be significant when p<0.05
Results and discussion
Test resultsopen allclose all
- Key result
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- not specified
- Key result
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- not specified
- Additional information on results:
- As a result of the main study, precipitation of test substance was observed at 250 μg/mL in 6-hour treatment series in presence of metabolic activation system at the start and end of the treatment.
In the 6-hour treatment series in the presence of metabolic activation system, the frequencies of metaphase(excluding gap) cells with structural chromosomal aberration were observed to be 0.67, 0.33, 0.33, and 0.00 % respectively for 0, 62.5, 125, and 250 μg/mL treated group. There was no statistically significant increase of metaphase cells with structural chromosomal aberration at any treatment groups when compared to the negative control group, and concentration-related increase was not observed. Also, the frequency of metaphase cells with structural chromosomal aberration was inside the 95 % confidence range of the historical negative control data. The frequencies of metaphase cells with numerical chromosomal aberration were observed to be 0.33, 0.33, 0.33, and 0.00 % respectively for 0, 62.5, 125, and 250 μg/mL treated group. There was no statistically significant increase of metaphase cells with numerical chromosomal aberration at any treatment groups when compared to the negative control group, and concentration-related increase was not observed. Also, the frequency of metaphase cells with numerical chromosomal aberration was inside the 95 % confidence range of the historical negative control data.
In the positive control group(B[a]P 5 μg/mL), the frequency of metaphase(excluding gap) cells with structural chromosomal aberration was 11.00 %, and there was a statistically significant increase when compared to the negative control group(p<0.05). The frequency of metaphase cells with numerical chromosomal aberration was 0.00 %, and there was no statistically significant increase when compared to the negative control group.
In the 6-hour treatment series in the absence of metabolic activation system, the frequencies of metaphase(excluding gap) cells with structural chromosomal aberration were observed to be 0.00, 0.33, 0.33, and 8.67 % respectively for 0, 16.9, 33.8, and 67.5 μg/mL treated group. There was a statistically significant increase of metaphase cells with structural chromosomal aberration at 67.5 μg/mL treated group when compared to the negative control group(p<0.05), and concentrationrelated increase was observed(p<0.05). Also, the frequency of metaphase cells with structural chromosomal aberration was outside the 95 % confidence range of the historical negative control data. The frequencies of metaphase cells with numerical chromosomal aberration were observed to be 0.33, 0.00, 0.00, and 0.00 % respectively for 0, 16.9, 33.8, and 67.5 μg/mL treated group. There was no statistically significant increase of metaphase cells with numerical chromosomal aberration at any treatment groups when compared to the negative control group, and concentration-related
increase was not observed. Also, the frequency of metaphase cells with numerical chromosomal aberration was inside the 95 % confidence range of the historical negative control data.
In the positive control group(4NQO 0.2 μg/mL), the frequency of metaphase(excluding gap) cells with structural chromosomal aberration was 4.67 %, and there was a statistically significant increase when compared to the negative control group(p<0.05). The frequency of metaphase cells with numerical chromosomal aberration was 0.00 %, and there was no statistically significant increase when compared to the negative control group.
In the 24-hour treatment series in the absence of metabolic activation system, the frequencies of metaphase(excluding gap) cells with structural chromosomal aberration were observed to be 0.00, 0.00, 0.00, and 5.33 % respectively for 0, 16.3, 32.5, and 65 μg/mL treated group. There was a statistically significant increase of metaphase cells with structural chromosomal aberration at 65 μg/mL treated group when compared to the negative control group(p<0.05), and concentrationrelated increase was observed(p<0.05). Also, the frequency of metaphase cells with structural chromosomal aberration was outside the 95 % confidence range of the historical negative control data. The frequencies of metaphase cells with numerical chromosomal aberration were observed to
be 0.33, 0.00, 0.00, and 0.00 % respectively for 0, 16.3, 32.5, and 65 μg/mL treated group. There was no statistically significant increase of metaphase cells with numerical chromosomal aberration at any treatment groups when compared to the negative control group, and concentration-related increase was not observed. Also, the frequency of metaphase cells with numerical chromosomal aberration was inside the 95 % confidence range of the historical negative control data.
In the positive control group(4NQO 0.2 μg/mL), the frequency of metaphase(excluding gap) cells with structural chromosomal aberration was 5.33 %, and there was a statistically significant increase when compared to the negative control group(p<0.05). The frequency of metaphase cells with numerical chromosomal aberration was 0.00 %, and there was no statistically significant increase when compared to the negative control group.
Applicant's summary and conclusion
- Conclusions:
- All validity criteria of this test were fulfilled.
In the 6-hour treatment series and 24-hour treatment series in the absence of metabolic activation system, there was a statistically significant increase of metaphase cells with structural chromosomal aberration when compared to the negative control group(p<0.05), and concentration-related increase was observed(p<0.05). Also, frequency of metaphase cells with structural chromosomal aberration was outside the 95 % confidence range of the historical negative control data.
In conclusion, the test substance, Fatty acids, C8-18 and C18-unsatd., zinc salts, was considered as inducing chromosomal aberration in the chinese hamster lung cells under the present study conditions.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.